Neurana Pharmaceuticals Inc.

May 12, 2020

Neurana Pharmaceuticals Announces Publication of a Driving Study Demonstrating the Effects of Tolperisone

Jun 17, 2019

Neurana Pharmaceuticals Announces Completion of Enrollment in the Phase 2 Study of Tolperisone in Acute Muscle Spasms of the Back

Feb 04, 2019

Neurana Pharmaceuticals Announces First Patient Enrolled in the "STAR Study," a Phase 2 Dose Ranging Study of Tolperisone in Acute Muscle Spasms of the Back

Oct 17, 2018

Neurana Pharmaceuticals to Present Tolperisone Phase 1 Clinical Data at the 2018 ACR/ARHP Annual Meeting

Oct 01, 2018

Neurana Pharmaceuticals to Present Clinical Data on Tolperisone at ACEP18

Jul 17, 2018

Neurana Pharmaceuticals Appoints Craig Thompson as President and CEO

May 07, 2018

Neurana Pharmaceuticals Announces Completion of $60 Million Series A Financing

Oct 26, 2017

Neurana Pharmaceuticals Reports Successful Results in Study Designed to Confirm the Non-Sedative Effects of Tolperisone, a Novel Skeletal Muscle Relaxant

Sep 26, 2017

Neurana Pharmaceuticals Completes Enrollment in Study Designed to Confirm the Non-Sedative Effects of Tolperisone, a Novel Skeletal Muscle Relaxant

Jul 26, 2017

Neurana Pharmaceuticals Initiates Study to Assess the Non-Sedating Properties of Tolperisone Among Healthy Volunteers